Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone

Free Abstracts

  Malignant Lymphoma

  Free Subscription


1 Bone Marrow Transplant
4 Br J Dermatol
2 Br J Haematol
1 Clin Med Insights Oncol
2 Int J Cancer
1 Lancet Oncol
3 Leuk Lymphoma
1 PLoS Genet
3 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Bone Marrow Transplant

  1. RE A, Gini G, Rupolo M, Levis A, et al
    Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk.
    Bone Marrow Transplant. 2017 Oct 9. doi: 10.1038/bmt.2017.
    PubMed     Text format    

    Br J Dermatol

  2. GELLER S, Myskowski PL, Kim YH, Moskowitz A, et al
    The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: Are we there yet?
    Br J Dermatol. 2017 Oct 10. doi: 10.1111/bjd.16052.
    PubMed     Text format     Abstract available

  3. KEMPF W
    TOX - what role does it play in cutaneous lymphomas?
    Br J Dermatol. 2016;175:248-9.
    PubMed     Text format    

    Targeting KIR3DL2 in primary cutaneous anaplastic large cell lymphomas.
    Br J Dermatol. 2016;175:246-7.
    PubMed     Text format    

    Cutaneous T-cell lymphomas: an urgent need for more improved therapies.
    Br J Dermatol. 2016;175:14-5.
    PubMed     Text format    

    Br J Haematol

  6. OTT G
    Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings.
    Br J Haematol. 2017;178:871-887.
    PubMed     Text format     Abstract available

  7. GOCKERITZ E, Vondey V, Guastafierro A, Pizevska M, et al
    Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue.
    Br J Haematol. 2017;178:949-953.
    PubMed     Text format     Abstract available

    Clin Med Insights Oncol

  8. ALLEN PB, Gordon LI
    Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.
    Clin Med Insights Oncol. 2017;11:1179554917731072.
    PubMed     Text format     Abstract available

    Int J Cancer

  9. COWELL JK, Qin H, Hu T, Wu Q, et al
    Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.
    Int J Cancer. 2017;141:1822-1829.
    PubMed     Text format     Abstract available

  10. BIASOLI I, Castro N, Delamain M, Silveira T, et al
    Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients - an analysis from the Brazilian Hodgkin Lymphoma Registry.
    Int J Cancer. 2017 Oct 11. doi: 10.1002/ijc.31096.
    PubMed     Text format     Abstract available

    Lancet Oncol

  11. BURKI TK
    Maintenance rituximab in mantle-cell lymphoma.
    Lancet Oncol. 2017 Oct 5. pii: S1470-2045(17)30773.
    PubMed     Text format    

    Leuk Lymphoma

  12. QUNAJ L, Castillo JJ, Olszewski AJ
    Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base.
    Leuk Lymphoma. 2017 Oct 11:1-9. doi: 10.1080/10428194.2017.1387912.
    PubMed     Text format     Abstract available

  13. VITAGLIANO O, Trastulli F, Cacace F, Leone S, et al
    Ibrutinib as salvage therapy in mantle cell lymphoma with central nervous system involvement in a pretreated unfit patient.
    Leuk Lymphoma. 2017 Oct 11:1-4. doi: 10.1080/10428194.2017.1387910.
    PubMed     Text format    

  14. CENCINI E, Puccini B, Rigacci L, Fabbri A, et al
    Radiotherapy plus rituximab as first-line regimen for localized follicular lymphoma.
    Leuk Lymphoma. 2017 Oct 10:1-7. doi: 10.1080/10428194.2017.1387909.
    PubMed     Text format     Abstract available

    PLoS Genet

  15. KING A, Li L, Wong DM, Liu R, et al
    Dynein light chain regulates adaptive and innate B cell development by distinctive genetic mechanisms.
    PLoS Genet. 2017;13:e1007010.
    PubMed     Text format     Abstract available

    PLoS One

  16. SZABO SM, Hirji I, Johnston KM, Juarez-Garcia A, et al
    Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study.
    PLoS One. 2017;12:e0180261.
    PubMed     Text format     Abstract available

  17. UCHIHARA Y, Ueda F, Tago K, Nakazawa Y, et al
    Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK.
    PLoS One. 2017;12:e0183003.
    PubMed     Text format     Abstract available

  18. PERSOON S, ChinAPaw MJM, Buffart LM, Liu RDK, et al
    Randomized controlled trial on the effects of a supervised high intensity exercise program in patients with a hematologic malignancy treated with autologous stem cell transplantation: Results from the EXIST study.
    PLoS One. 2017;12:e0181313.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.